Literature DB >> 2806356

Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model.

M V Pimm1, L G Durrant, R W Baldwin.   

Abstract

A monoclonal antibody, against a colorectal carcinoma tumour-associated antigen, was radioiodinated and its biodistribution studied in comparison with that of control immunoglobulin in nude mice with colon carcinoma xenografts. Tumour localization of the antibody in comparison with normal tissues was poor, and in absolute terms more control IgG than antibody was present per gram of tumour. This failure to achieve localization could not be ascribed to poor immunoreactivity of the antibody nor to the failure of the xenografts to express the appropriate antigen. Analysis of serum from mice with xenografts showed the presence of circulating tumour-derived antigen. This serum-borne antigen was found to form immune complexes both in vitro and in vivo with the monoclonal antibody, and this complex formation is probably the limiting factor in tumour localization of the antibody. This is one of only few examples where mice with human tumour xenografts have levels of circulating antigen sufficient to perturb biodistribution of antibody. These findings are relevant to the biodistribution of monoclonal antibodies in the clinical situation, since circulating antigen is often found in cancer patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2806356     DOI: 10.1016/0277-5379(89)90080-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  6 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.

Authors:  M Perälä-Heape; P Vihko; A Laine; J Heikkilä; R Vihko
Journal:  Eur J Nucl Med       Date:  1991

3.  Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies.

Authors:  M V Pimm; R S Rajput; M Frier; S J Gribben
Journal:  Eur J Nucl Med       Date:  1991

4.  Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.

Authors:  Y S Chung; T Sawada; Y Kondo; K Hirayama; A Inui; Y Yamashita; B Nakata; T Okamura; H Ochi; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1997-04

Review 5.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04

6.  Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.

Authors:  H Kobayashi; B F Sun; E S Han; M K Kim; N Le; Q C Wang; D L Nelson; I Pastan; T A Waldmann; C H Paik; J A Carrasquillo
Journal:  Jpn J Cancer Res       Date:  1998-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.